Day: March 30, 2023

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 18932 DKT 01/06/23 II 4,200 3,120 2.63 100 % 99.570898 19070 DKT 01/09/23 III 5,700 5,700 2.85 100 % 98.8187Total 9,900 8,820      The sale will settle 3 April 2023.

We expect to release the Q1 2023 results of DSV A/S in the morning of 27 April 2023. A webcast and conference call will be held at 11:00 am CEST. At the call, Group CEO Jens Bjørn Andersen, Group COO Jens Lund and Group CFO Michael Ebbe will present the Q1 2023 Interim Financial Report. The presentation will be followed by a Q&A session. Date:                 27 April 2023Time:                 11:00 am CEST To attend the conference call, you may do one of the following:       a.   Webcast Go to investor.dsv.com or https://dsv-events.eventcdn.net/events/interim-report-first-quarter-2023       b.   Conference call Participant dial-in telephone numbers: DK: +45 78 76 84 90UK: +44 (0) 203 769 6819US: +1 646 787 0157 (PIN 882 686) We recommend participants to dial in 10 minutes prior to the scheduled start time. Contacts Investor RelationsFlemming...

March 30, 2023Announcement no. 4 BioPorto Announces Annual Results for the Year ended December 31, 2022 COPENHAGEN, Denmark and BOSTON, MA, USA, March 30, 2023, (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced financial results for the year ended December 31, 2022 and business progress for the fourth quarter of 2022. Recent HighlightsFor the year ended December 31, 2022:Total revenue of DKK 29.0 million / USD 4.1 million, a 19% increase over the prior year Adjusted EBITDA of DKK (67.3) million / USD (9.5) million Cash and cash equivalents of DKK 81.8 million / USD 11.7 million as of December 31, 2022 (DKK 45.5 million / USD 6.9 million as of December 31, 2021)For the fourth quarter ending December 31, 2022:Total revenue of DKK 8.7 million / USD 1.2 million, a 28% increase over the prior year Adjusted...

Paris, March 30th, 2023 Change to the financial calendar Due to calendar constraints, the Air France-KLM Group will publish its First Quarter 2023 results on May 5th, 2023, before market opening instead of the initially scheduled date of May 4th, 2023. The other dates in the financial calendar remain unchanged and are available here. Investor Relations                                                         Michiel Klinkers                        Marouane Mami                                                             michiel.klinkers@airfranceklm.com        mamami@airfranceklm.com Website: www.airfranceklm.comAttachment30 MARCH – PR – postponement of Q1 23 results

SAMPO PLC                STOCK EXCHANGE RELEASE        30 March 2023 at 9:15 am Demerger plan of Sampo plc registered in Finnish Trade Register The demerger plan of Sampo plc approved and signed by the Board of Directors of Sampo plc on 29 March 2023 has today been registered in Finnish Trade Register. According to the demerger plan, the separation of Mandatum from Sampo plc would be carried out via a partial demerger. The partial demerger of Sampo plc requires an approval of Sampo’s Annual General Meeting of 17 May 2023. The demerger plan and the Board’s proposal on the partial demerger of Sampo plc is available at www.sampo.com/demerger. SAMPO PLC Investor Relations and Group Communications For further information, please contact: Sami TaipalusHead of Investor Relationstel. +358 10 516 0030 Distribution:Nasdaq HelsinkiNasdaq StockholmLondon...

LONDON and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company’s ADSs on NASDAQ at a price of US$1.41 per ADS (which would be equivalent to the purchase of 715,000 ordinary shares of no par value (“Ordinary Shares”) at a price of £0.0176 each).1. Details of PDMR / person closely associateda) Name Gabriele Cerrone2. Reason for the notificationa) Position / status Chairmanb) Initial...

Advanced ultra-low carbon thin film modules to power US projects, with deliveries up to 2028EDP Renewables Places Multi-Year Order for 1.8 GW of First Solar Modules First Solar, Inc. and EDP Renewables today announced a multi-year order for 1.8 gigawatts of First Solar’s advanced thin film photovoltaic (PV) solar modules. The modules, which will be delivered up to 2028, will power US projects developed by EDP Renewables North America.TEMPE, Ariz. and HOUSTON, Texas, March 30, 2023 (GLOBE NEWSWIRE) — First Solar, Inc. (NASDAQ: FSLR) and EDP Renewables (Euronext: EDPR) today announced a multi-year order for 1.8 gigawatts (GWdc) of First Solar’s advanced thin film photovoltaic (PV) solar modules. The modules, which will be delivered up to 2028, will power US projects developed by EDP Renewables North America (EDPR NA). EDP Renewables...

Trondheim, 30 March 2023: The Annual General Meeting of NORBIT ASA will be held on Thursday 4 May 2023 at 4:00 pm at the company’s headquarter in Stiklestadveien 1, 7041 Trondheim, Norway. Shareholders who are not able to physically attend the meeting are encouraged to vote in advance or submit a proxy form prior to the meeting. Attached please find the following documents:The notice of the general meeting, including the proposed resolutions and attendance and proxy forms The proposal from the nomination committee for the general meeting The guidelines for remuneration to the senior executives The board of directors’ report on salary and other remuneration for leading personnel for 2022 Recommendation on selection of auditor The proposed new articles of associationAll documents to be processed in the meeting, including access to electronic...

CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022 ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the full-year ended December 31, 2022, and provided a corporate update. “Our partner, Janssen made excellent progress in advancing the ADX71149 phase 2 clinical study in epilepsy patients and we look forward to the recommendation from the independent interim review committee, established to review the data from part 1,” said Tim Dyer CEO of Addex....